InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+23.6%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Nicola Beltraminelli, Vice-président, Chief Development Officer. Director active across 1 company, notably Innate Pharma. Cumulatively, 3 reports have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €166k. Activity tracked since 5 January 2026. The latest transaction was disclosed on 31 December 2025 (Acquisition). Regulator: AMF. All data is openly available.
Declarations3 total
50,000 shares@ €1.61648.7% of flowActionEuronext Paris2026DD1086888
Ideal exit: 27 Sept 2026 (T+270)
50,000 shares@ €1.60848.5% of flowActionEuronext Paris2026DD1089552
Ideal exit: 27 Sept 2026 (T+270)
3,000 shares@ €1.572.8% of flowActionEuronext Paris2026DD1088617
3 of 3 declarations
About Nicola Beltraminelli
Dr. Nicola Beltraminelli is an experienced biotechnology executive and currently serves as Vice President, Chief Development Officer at Innate Pharma. He joined the company in January 2022, bringing more than 20 years of experience in biologics development, from early discovery through GMP manufacturing. His career has been strongly focused on development strategy, CMC operations, and the industrialization of biologic candidates—capabilities that are particularly important for a listed biotech company advancing oncology assets toward the clinic. Before joining Innate Pharma, Beltraminelli was Chief Technical Officer at Lysogene, where he led CMC activities for two late-stage development assets. In that role, he gained hands-on leadership experience across formulation, manufacturing, development planning, and regulatory preparation. Prior to Lysogene, he held senior positions at HiFiBiO Therapeutics and BliNK Biomedical SAS. At HiFiBiO, he led the French site’s R&D activities as well as the company’s global CMC efforts, helping advance three projects into the clinic. At Innate Pharma, he plays a key role in progressing the company’s portfolio in immuno-oncology. His background combines scientific depth, operational rigor, and strong experience in biologics development across growing biotech organizations. He holds a PhD in Molecular Biology from the University of Lausanne and also serves as a board member of MabDesign. With his expertise in development, GMP compliance, and cross-functional program execution, he is a central figure in turning scientific innovation into clinical-stage therapeutic candidates and future partnering opportunities.
